Testosterone Cypionate Non-Responder Profile: Who Doesn't Respond and Why

Is there a real non-responder profile?

No clinical test is established for predicting who will feel better on testosterone cypionate. Androgen-receptor CAG repeat length remains a research question, and its usefulness for individual assessment has not been established [6].

The Depo-Testosterone label says to confirm hypogonadism with morning serum testosterone measured on at least two separate days, both below the normal range, and says dosage is adjusted according to the patient's response and adverse reactions [3]. Its indication is replacement for primary hypogonadism (testicular failure) or hypogonadotropic hypogonadism (pituitary or hypothalamic cause) [3].

The label says about 98 percent of plasma testosterone is bound and roughly 2 percent is free, with sex hormone-binding globulin determining the split [3]. The Endocrine Society guideline recommends measuring free testosterone when total testosterone is near the lower limit of normal or when a condition alters SHBG [5].

Which outcomes respond, and which do not

In the T Trials, 790 men aged 65 and older with testosterone below 275 ng/dL received testosterone gel or placebo gel for one year [1]. Sexual activity, sexual desire and erectile function all improved significantly; vitality on the FACIT-fatigue scale did not [1].

In a dose-response study, 61 healthy men aged 18 to 35 had their own testosterone production suppressed with a GnRH agonist, then received weekly testosterone enanthate injections of 25, 50, 125, 300 or 600 mg for 20 weeks [2]. Fat-free mass rose with dose, by 3.4, 5.2 and 7.9 kg at 125, 300 and 600 mg, and leg press strength, leg power, hemoglobin and IGF-I also tracked dose, while sexual function, mood and PSA did not change significantly at any dose [2].

Neither trial used testosterone cypionate: one used gel, the other enanthate injections in men whose own production had been switched off [1][2]. They show that sexual outcomes and vitality can respond differently, and they cannot identify a cypionate non-responder profile.

Label safety points for men on cypionate

Injectable testosterone can raise hematocrit. Across 29 randomized trials, intramuscular enanthate or cypionate raised mean hematocrit by 4.0 percent versus placebo [4]. The Depo-Testosterone label lists polycythemia as an adverse reaction and says to check hemoglobin and hematocrit periodically during long-term use [3].

The label also states that testosterone can increase blood pressure, that blood pressure should be monitored periodically, and that testosterone products are not recommended in men with uncontrolled hypertension [3]. Depression, anxiety and libido changes appear among its listed adverse reactions [3], as does gynecomastia, which "may develop and occasionally persists" [3].